Interestingly, we found a longer OS (10 vs. 3 months, p = 0.02) for patients with an excluded immune-infiltrate but high numbers of CD8+ CTL in the tumor surrounding stroma when compared to patients with a smaller number of CD8+ CTL in the stroma. The gene discussed is CD8A; the disease is neoplasm.